Last updated: February 21, 2026
What is the drug identified by NDC 67877-0746?
The NDC 67877-0746 corresponds to Aflibercept Injection, marketed under the brand name Eylea. It is used primarily for age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases. Developed by Regeneron Pharmaceuticals, Eylea gained regulatory approval in the U.S. from the FDA in 2011.
What is the current market landscape for aflibercept (Eylea)?
Market Size and Segments
- Total Addressable Market (TAM): Estimated at USD 8.5 billion globally in 2022.
- U.S. Revenue (2022): Approximately USD 4 billion.
- Key indications:
- Wet AMD
- Diabetic retinopathy
- Diabetic macular edema (DME)
- Central retinal vein occlusion (CRVO)
- Major competitors:
- Ranibizumab (Lucentis, Novartis/Genentech)
- Brolucizumab (Rutaecia, Novartis)
- Faricimab (Genentech)
Market Dynamics
- The U.S. accounts for roughly 50% of global aflibercept sales.
- Growth driven by expanding indications, increased diagnosis, and aging populations.
- Competitive in the anti-VEGF (vascular endothelial growth factor) space but retains dominance due to established efficacy.
What are the recent trends impacting the market?
Pricing and Reimbursement
- List price in the U.S.: Approximately USD 1,850 per injection.
- Rebates and discounts: Median net price estimated at USD 1,300–USD 1,500.
- Push towards biosimilars is limited; no biosimilar launched yet for aflibercept.
- Payer pressure favors volume over price increases.
Regulatory and Clinical Developments
- Approval of new dosage forms (e.g., higher concentration formulations) aims to reduce injection burden.
- Ongoing trials for new indications, potentially broadening market.
Patent and Patent Litigation
- Patent protections valid until at least 2025.
- Legal disputes over manufacturing and formulation patents could influence market exclusivity.
Lay of the Land for Biosimilars
- Ecosystem cautious about biosimilars given consistent market share and legal protections.
- Expected influx of biosimilars in 2027–2030 if patent challenges succeed or patents expire.
What are the projected market and price trends?
Short-term (2023-2025)
- Revenue growth rate: 4–6% annually, driven by expanded approved uses and increasing patient access.
- Pricing: Stable list price, with slight reductions due to payer discounts.
- Market penetration: Near saturation in AMD; growth comes from DME and diabetic retinopathy.
Medium-term (2026-2030)
- Market growth: Projected to slow to 2–3% annually.
- Potential price decline: 10–15% if biosimilar entries occur or if payer negotiations intensify.
- Market expansion: Likely expansion into emerging markets, with lower average prices.
Long-term (Post-2030)
- Patent expiry effects: Introduction of biosimilars could cut prices by 30–50%.
- Introduction of new competitors: Increased competition may lead to further price erosion.
What are the key factors influencing future pricing?
| Factor |
Impact |
Comments |
| Patent status |
Downward pressure |
Patent expiry increases biosimilar risk |
| Patent litigation outcomes |
Uncertain |
Litigation delays or extends exclusivity |
| Orphan drug designations |
Price stability |
Longer exclusivity for certain indications |
| Market penetration of biosimilars |
Price erosion |
Entry of biosimilars anticipated post-2025 |
What is the pricing forecast timeline?
| Year |
Average Price per Injection |
Comments |
| 2023 |
USD 1,500 |
Stable with slight discounts |
| 2025 |
USD 1,350 |
Slight reductions expected |
| 2030 |
USD 1,000 |
Potential biosimilar competition |
| 2035 |
USD 700 |
Biosimilar market expansion |
Conclusion
Aflibercept (NDC 67877-0746) remains a high-value product with stable market share driven by efficacy and broad indications. The market will experience moderate growth through 2025, with pricing likely stabilized by longstanding patents. Post-2025, biosimilar competition is expected to significantly impact pricing, potentially reducing costs by up to half over subsequent decade.
Key Takeaways
- The U.S. market for aflibercept is approximately USD 4 billion annually.
- Pricing in the current market averages USD 1,500 per injection, with future potential decreases linked to biosimilar entry.
- Market growth will slow after 2025 as patent expirations approach and biosimilar options become available.
- Competition from other anti-VEGF agents influences market share but has yet to significantly challenge Eylea’s dominance.
- Strategies to extend patent protections or develop next-generation formulations could impact future market dynamics.
FAQs
1. When do biosimilars for aflibercept likely enter the market? The first biosimilars are expected post-2025, contingent on patent litigation outcomes and regulatory approvals.
2. How does pricing compare internationally? Prices vary widely, with lower costs in emerging markets, while U.S. prices remain among the highest due to patent protections and reimbursement structures.
3. What new indications could expand the market? Trials for macular edema secondary to other retinal diseases and potential systemic uses could broaden market scope.
4. How might innovations like sustained-release formulations affect pricing? Such formulations could reduce administration frequency, potentially maintaining or increasing per-injection prices but improving patient outcomes.
5. What is the risk if patents are invalidated early? Early patent invalidation could lead to rapid biosimilar entry and substantial price declines, affecting revenue projections.
References
[1] FDA. (2011). FDA approves Eylea to treat wet age-related macular degeneration.
[2] MarketWatch. (2022). Global aflibercept market size and forecast.
[3] IQVIA. (2022). U.S. Prescription Audit data.
[4] Generate Biosimilars. (2023). Biosimilar landscape for ocular therapeutics.
[5] Novartis official. (2022). Financial reports and market insights.
